CTNNB1

Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)

Retrieved on: 
Monday, April 15, 2024
SLATE, Mutation, Safety, HLA, Trial of the century, National Cancer Institute, Vaccine, Gritstone bio, Human, Antigen presentation, BRAF, Oncogene, Patient, TP53, NCI, CTNNB1, Pharmaceutical industry

EMERYVILLE, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, announced today that a paper detailing the development of its “off-the-shelf” neoantigen platform, SLATE, recently published in Nature Medicine. The paper, “A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results,” describes a novel immunodominance hierarchy of tumor neoantigens (including KRAS) that Gritstone discovered in Phase 1 translational studies and leveraged to develop SLATE-KRAS, a “pure” KRAS-directed candidate that demonstrated superior immunogenicity to the initial version in a subsequent Phase 2 study and is currently being evaluated in a novel cell therapy-vaccine combination study run by Steven A. Rosenberg of the National Cancer Institute (NCT06253520).

Key Points: 
  • "Our team’s innovative work to develop, optimize and validate SLATE positions Gritstone with two promising platforms to execute against our neoantigen-directed approach to oncology.
  • Neoantigens were identified using Gritstone bio’s proprietary neoantigen prediction platform, EDGETM, and selected based on shared mutation and matched HLA frequencies in patient populations with solid tumors.
  • These data led to the development of SLATE-KRAS, a vaccine focused on KRAS-derived neoantigens that subsequently was evaluated in the Phase 2 portion of the clinical study.
  • Initial Phase 2 data suggesting an increased vaccine induced T cell response were presented in September 2022 ( press release ).

Cellworks Personalized Biosimulation Study Identifies Novel MDS Biomarkers and Immune Modulation Predictive of Therapy Response

Retrieved on: 
Tuesday, December 14, 2021
Data Management, Biotechnology, Technology, Health, General Health, Pharmaceutical, Oncology, Research, Software, Science, Clinical Trials, TRRAP, Personalized medicine, Clinical trial, MDS, Abstract, AZA, Disease, CBM, Drug resistance, Antigen, Biosimulation, HMA, Biomarker, Artificial intelligence, Myelodysplastic syndrome, CAV1, DAC, KDM4C, IFNA1, JAK2, MD, ASH, Society, Monosomy, Group, HIPK2, Research, Exposition, Agilent Technologies, DNA, VPA, HDAC, Software, Drug combination, Sequoia Capital, GSK3B, CD8, CTNNB1, Immunology, Azacitidine, UnitedHealth Group, Escape Room, Neoplasm, Patient, CD274, Medical device, Vaccine, Pharmaceutical industry, Decitabine

In the ASH Abstract 3690 study, the Cellworks Biosimulation Platform and CBM identified immune modulation as a key pathway for predicting azacitidine (AZA) response in MDS.

Key Points: 
  • In the ASH Abstract 3690 study, the Cellworks Biosimulation Platform and CBM identified immune modulation as a key pathway for predicting azacitidine (AZA) response in MDS.
  • The Cellworks Biosimulation Platform simulates how a patient's personalized genomic disease model will respond to therapies prior to treatment and identifies novel drug combinations for treatment-refractory patients.
  • Cellworks Biosimulation Platform found that signaling pathway consequences related to CTNNB1 and c-MYC modulation predict response to DAC + VPA.
  • Biosimulation using the Cellworks Computational Omics Biology Model (CBM) identifies immune modulation as a key pathway for predicting azacitidine (AZA) response in MDS.